LT3313838T - Policikliniai amido dariniai, kaip cdk9 slopikliai - Google Patents

Policikliniai amido dariniai, kaip cdk9 slopikliai

Info

Publication number
LT3313838T
LT3313838T LTEP16733459.8T LT16733459T LT3313838T LT 3313838 T LT3313838 T LT 3313838T LT 16733459 T LT16733459 T LT 16733459T LT 3313838 T LT3313838 T LT 3313838T
Authority
LT
Lithuania
Prior art keywords
amide derivatives
cdk9 inhibitors
polycyclic amide
polycyclic
cdk9
Prior art date
Application number
LTEP16733459.8T
Other languages
English (en)
Inventor
Kurt Pike
Bernard Barlaam
Janet Hawkins
Christopher De Savi
Melissa Vasbinder
Alexander Hird
Michelle Lamb
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of LT3313838T publication Critical patent/LT3313838T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Detergent Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP16733459.8T 2015-06-29 2016-06-27 Policikliniai amido dariniai, kaip cdk9 slopikliai LT3313838T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562185852P 2015-06-29 2015-06-29
PCT/EP2016/064899 WO2017001354A1 (en) 2015-06-29 2016-06-27 Polycyclic amide derivatives as cdk9 inhibitors

Publications (1)

Publication Number Publication Date
LT3313838T true LT3313838T (lt) 2019-06-10

Family

ID=56292699

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP16733459.8T LT3313838T (lt) 2015-06-29 2016-06-27 Policikliniai amido dariniai, kaip cdk9 slopikliai
LTEP19165726.1T LT3539961T (lt) 2015-06-29 2016-06-27 Policikliniai amido dariniai, kaip cdk9 inhibitoriai

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP19165726.1T LT3539961T (lt) 2015-06-29 2016-06-27 Policikliniai amido dariniai, kaip cdk9 inhibitoriai

Country Status (36)

Country Link
US (4) US9845331B2 (lt)
EP (2) EP3313838B1 (lt)
JP (1) JP6997627B2 (lt)
KR (1) KR102663113B1 (lt)
CN (1) CN107873028B (lt)
AR (1) AR105179A1 (lt)
AU (1) AU2016286200B2 (lt)
BR (1) BR122019013677B1 (lt)
CA (1) CA2989499C (lt)
CL (1) CL2017003306A1 (lt)
CO (1) CO2017013713A2 (lt)
CR (2) CR20210297A (lt)
CY (2) CY1122111T1 (lt)
DK (2) DK3313838T3 (lt)
DO (2) DOP2017000295A (lt)
EA (1) EA035383B1 (lt)
ES (2) ES2728356T3 (lt)
HR (2) HRP20211970T1 (lt)
HU (2) HUE043440T2 (lt)
IL (1) IL256393B (lt)
LT (2) LT3313838T (lt)
ME (1) ME03404B (lt)
MX (1) MX371034B (lt)
NI (1) NI201700174A (lt)
PE (1) PE20180530A1 (lt)
PH (1) PH12017502334A1 (lt)
PL (2) PL3313838T3 (lt)
PT (2) PT3539961T (lt)
RS (2) RS58712B1 (lt)
SI (2) SI3313838T1 (lt)
SV (1) SV2017005598A (lt)
TN (1) TN2017000486A1 (lt)
TR (1) TR201909286T4 (lt)
TW (1) TWI723028B (lt)
WO (1) WO2017001354A1 (lt)
ZA (1) ZA201800563B (lt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020005039A2 (pt) 2017-09-25 2020-09-15 Astrazeneca Ab combinação de um inibidor de btk e um inibidor de cdk9 para tratar câncer
US11319295B2 (en) 2017-10-09 2022-05-03 Merck Sharp & Dohme Corp. Substituted phenyloxetane and phenyltetrahydrofuran compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
CN108129288B (zh) * 2017-12-27 2021-01-22 上海毕得医药科技股份有限公司 一种反式-3-羟基环丁基甲酸的合成方法
TW202344250A (zh) 2018-11-14 2023-11-16 瑞典商阿斯特捷利康公司 治療癌症之方法
KR20220079851A (ko) * 2019-09-11 2022-06-14 프렐루드 테라퓨틱스, 인코포레이티드 Cdk 억제제 및 약제로서의 이의 용도
US20230102081A1 (en) * 2019-12-09 2023-03-30 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Compound as cyclin-dependent kinase 9 inhibitor and use thereof
US20230219961A1 (en) * 2020-05-12 2023-07-13 Suzhou Alphama Biotechnology Co., Ltd. Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof
WO2021227904A1 (zh) * 2020-05-12 2021-11-18 苏州阿尔脉生物科技有限公司 一种作为cdk9抑制剂的多环酰胺类衍生物、其制备方法及用途
JP2023542065A (ja) 2020-06-24 2023-10-05 アストラゼネカ ユーケー リミテッド 抗体－薬物複合物及びｃｄｋ９阻害剤の組み合わせ
WO2022028556A1 (zh) 2020-08-07 2022-02-10 南京药石科技股份有限公司 Cdk9抑制剂及其用途
TWI809330B (zh) * 2020-11-20 2023-07-21 大陸商勁方醫藥科技(上海)有限公司 Cdk9抑制劑的多晶型物及其製法和用途
WO2022247796A1 (zh) * 2021-05-24 2022-12-01 石药集团中奇制药技术（石家庄）有限公司 周期蛋白依赖性激酶9抑制剂的用途
WO2022247785A1 (zh) * 2021-05-24 2022-12-01 石药集团中奇制药技术（石家庄）有限公司 一种周期蛋白依赖性激酶9抑制剂的用途
CN117813289A (zh) * 2021-07-14 2024-04-02 上海海雁医药科技有限公司 吡唑衍生物及其中间体和制备方法
TW202333679A (zh) * 2021-12-23 2023-09-01 比利時魯汶大學 用於抑制ｙａｐ／ｔａｚ－ｔｅａｄ之四氫吡唑并嘧啶及相關類似物
WO2024039210A1 (ko) 2022-08-17 2024-02-22 한국화학연구원 Cdk2 및/또는 cdk9의 억제 또는 분해용 화합물 및 이들의 의약 용도

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008133192A1 (ja) 2007-04-19 2008-11-06 Takeda Pharmaceutical Company Limited 縮合イミダゾール化合物およびその用途
JP5566879B2 (ja) 2007-04-24 2014-08-06 インゲニウム ファーマシューティカルズ ジーエムビーエイチ プロテインキナーゼの阻害剤
US8436007B2 (en) 2007-04-24 2013-05-07 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
EP2137166B1 (en) 2007-04-24 2012-05-30 Ingenium Pharmaceuticals GmbH 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases
WO2008129071A1 (en) 2007-04-24 2008-10-30 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
WO2008132138A1 (en) 2007-04-25 2008-11-06 Ingenium Pharmaceuticals Gmbh Derivatives of 4,6-disubstituted aminopyrimidines
BRPI0818543A2 (pt) 2007-10-12 2018-10-23 Ingenium Pharmaceuticals Gmbh inibidores de proteína cinase
EP2473502A1 (en) 2009-09-04 2012-07-11 Novartis AG Heteroaryl compounds as kinase inhibitors
US20110113038A1 (en) 2009-11-12 2011-05-12 International Business Machines Corporation Search term security
GB201002911D0 (en) 2010-02-19 2010-04-07 Medical Res Council Compound
NZ627520A (en) 2010-03-10 2015-10-30 Astrazeneca Ab 4-phenyl pyridine analogues as protein kinase inhibitors
AR081810A1 (es) 2010-04-07 2012-10-24 Bayer Cropscience Ag Piridinilpirazoles biciclicos
WO2012066065A1 (en) 2010-11-17 2012-05-24 Novartis Ag Phenyl-heteroaryl amine compounds and their uses
EP2668162A1 (en) * 2011-01-28 2013-12-04 Novartis AG Substituted bi-heteroaryl compounds as cdk9 inhibitors and their uses
WO2012101064A1 (en) * 2011-01-28 2012-08-02 Novartis Ag N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
WO2012101063A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyridine biaryl compounds and their uses
MX351460B (es) 2011-10-06 2017-10-16 Bayer Ip Gmbh Heterociclilpiri(mi)dinilpirazol.
AU2014244263A1 (en) 2013-03-13 2015-08-13 Abbvie Inc. CDK9 kinase inhibitors
CA2901334A1 (en) 2013-03-13 2014-10-02 Abbvie Inc. Pyridine cdk9 kinase inhibitors
MX2015012153A (es) 2013-03-14 2015-12-01 Abbvie Inc Inhibidores de la quinasa pirrolopirimidina cdk9.
TW201444836A (zh) 2013-03-14 2014-12-01 Abbvie Inc 吡咯并［２，３－ｂ］吡啶ｃｄｋ９激酶抑制劑

Also Published As

Publication number Publication date
CN107873028A (zh) 2018-04-03
TW201718573A (zh) 2017-06-01
NI201700174A (es) 2018-10-19
PE20180530A1 (es) 2018-03-19
TN2017000486A1 (en) 2019-04-12
AU2016286200A1 (en) 2018-02-08
CN107873028B (zh) 2021-02-02
BR112017027394A2 (pt) 2018-11-06
US20180093998A1 (en) 2018-04-05
BR122019013677B1 (pt) 2024-01-02
SI3539961T1 (sl) 2022-02-28
JP6997627B2 (ja) 2022-01-17
CY1125066T1 (el) 2023-03-24
EA201890094A1 (ru) 2018-07-31
WO2017001354A1 (en) 2017-01-05
ZA201800563B (en) 2022-08-31
CR20170596A (es) 2018-07-04
RS58712B1 (sr) 2019-06-28
PL3539961T3 (pl) 2022-02-14
EP3539961B1 (en) 2021-10-06
CY1122111T1 (el) 2020-11-25
DK3313838T3 (da) 2019-06-11
CL2017003306A1 (es) 2018-06-29
PL3313838T3 (pl) 2019-08-30
CR20210297A (es) 2021-09-29
MX2017016244A (es) 2018-04-20
KR102663113B1 (ko) 2024-05-02
PT3313838T (pt) 2019-06-24
DK3539961T3 (da) 2022-01-03
CA2989499A1 (en) 2017-01-05
DOP2018000207A (es) 2018-10-15
ES2728356T3 (es) 2019-10-23
TR201909286T4 (tr) 2019-07-22
US20210171541A1 (en) 2021-06-10
CO2017013713A2 (es) 2018-03-28
HUE043440T2 (hu) 2019-08-28
IL256393A (en) 2018-02-28
DOP2017000295A (es) 2017-12-31
US9845331B2 (en) 2017-12-19
MX371034B (es) 2020-01-13
US11352369B2 (en) 2022-06-07
KR20180021830A (ko) 2018-03-05
EA035383B1 (ru) 2020-06-04
EP3313838A1 (en) 2018-05-02
IL256393B (en) 2021-12-01
AU2016286200B2 (en) 2018-10-04
US10717746B2 (en) 2020-07-21
HRP20211970T1 (hr) 2022-03-18
PT3539961T (pt) 2021-12-20
HUE057343T2 (hu) 2022-05-28
EP3539961A1 (en) 2019-09-18
JP2018522869A (ja) 2018-08-16
SV2017005598A (es) 2018-02-23
TWI723028B (zh) 2021-04-01
ES2902148T3 (es) 2022-03-25
AR105179A1 (es) 2017-09-13
HRP20190748T1 (hr) 2019-06-14
RS62781B1 (sr) 2022-01-31
EP3313838B1 (en) 2019-04-03
PH12017502334A1 (en) 2018-06-25
LT3539961T (lt) 2021-12-27
SI3313838T1 (sl) 2019-06-28
US20220340592A1 (en) 2022-10-27
US20160376287A1 (en) 2016-12-29
ME03404B (me) 2020-01-20
CA2989499C (en) 2023-10-31

Similar Documents

Publication Publication Date Title
ZA201800563B (en) Polycyclic amide derivatives as cdk9 inhibitors
ME03740B (me) Jedinjenja indol karboksamida korisna kao inhibitori kinaze
IL266745A (en) Benzodiazolonium compounds as enac inhibitors
HK1257565A1 (zh) 作為htra1抑制劑的新型三氟甲基丙酰胺衍生物
HK1257567A1 (zh) 作為htra1抑制劑的新型二氟酮酰胺衍生物
HK1253572A1 (zh) 作為tnap抑制劑的吡啶並噁嗪酮化合物
IL258438B (en) 2-Aminoquinoline derivatives as p70s6 kinase inhibitors
HK1252767A1 (zh) 作為eaat3抑制劑的吡唑-吡啶衍生物